Targeted therapy of hepatocellular cancer

Bibliography

• Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-16
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153-6
   PubMed Web of Science ®Google Scholar
• Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97(1):72-81
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50
   PubMed Web of Science ®Google Scholar
• Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6(9):674-87
   PubMed Web of Science ®Google Scholar
• Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31(4):339-46
   PubMed Web of Science ®Google Scholar
• Villanueva A, Newell P, Chiang DY, Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27(1):55-76
   PubMed Web of Science ®Google Scholar
• Brechot C, Pourcel C, Louise A, Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286(5772):533-5
   PubMed Web of Science ®Google Scholar
• Murakami Y, Saigo K, Takashima H, Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005;54(8):1162-8
   PubMed Web of Science ®Google Scholar
• Minami M, Daimon Y, Mori K, Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 2005;24(27):4340-8
   PubMed Web of Science ®Google Scholar
• Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990;343(6258):555-7
   PubMed Web of Science ®Google Scholar
• Feitelson MA, Duan LX. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997;150(4):1141-57
   PubMed Web of Science ®Google Scholar
• Balsano C, Avantaggiati ML, Natoli G, Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun 1991;176(3):985-92
   PubMed Web of Science ®Google Scholar
• Twu JS, Lai MY, Chen DS, Robinson WS. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology 1993;192(1):346-50
   PubMed Web of Science ®Google Scholar
• Chirillo P, Falco M, Puri PL, Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J Virol 1996;70(1):641-6
   PubMed Web of Science ®Google Scholar
• Seto E, Mitchell PJ, Yen TS. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 1990;344(6261):72-4
   PubMed Web of Science ®Google Scholar
• Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Int J Oncol 1999;15(2):373-9
   PubMed Web of Science ®Google Scholar
• Lee YH, Yun Y. HBx protein of hepatitis B virus activates Jak1-STAT signaling. J Biol Chem 1998;273(39):25510-5
   PubMed Web of Science ®Google Scholar
• Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994;91(22):10350-4
   PubMed Web of Science ®Google Scholar
• Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004;39(6):1683-93
   PubMed Web of Science ®Google Scholar
• Ueda H, Ullrich SJ, Gangemi JD, Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9(1):41-7
   PubMed Web of Science ®Google Scholar
• Lee SW, Lee YM, Bae SK, Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun 2000;268(2):456-61
   PubMed Web of Science ®Google Scholar
• Yamanaka T, Kodama T, Doi T. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem Biophys Res Commun 2002;294(3):528-34
   PubMed Web of Science ®Google Scholar
• Fukutomi T, Zhou Y, Kawai S, Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005;41(5):1096-105
   PubMed Web of Science ®Google Scholar
• Florese RH, Nagano-Fujii M, Iwanaga Y, Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res 2002;90(1-2):119-31
   PubMed Web of Science ®Google Scholar
• Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338(8779):1356-9
   PubMed Web of Science ®Google Scholar
• Terasaki S, Kaneko S, Kobayashi K, Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 1998;115(5):1216-22
   PubMed Web of Science ®Google Scholar
• Watanabe S, Horie Y, Kataoka E, Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol 2007;22(Suppl 1):S96-S100
   PubMedGoogle Scholar
• Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009;44(Suppl 19):96-101
   PubMedGoogle Scholar
• Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004;5(10):836-47
   PubMed Web of Science ®Google Scholar
• Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19(4):318-25
   PubMedGoogle Scholar
• Hisaka T, Yano H, Haramaki M, Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol 1999;14(3):453-60
   PubMed Web of Science ®Google Scholar
• Ito Y, Takeda T, Higashiyama S, Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 2001;8(4):903-7
   PubMed Web of Science ®Google Scholar
• Huether A, Hopfner M, Baradari V, EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005;70(11):1568-78
   PubMed Web of Science ®Google Scholar
• Hopfner M, Sutter AP, Huether A, Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004;41(6):1008-16
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23(27):6657-63
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110(5):1059-67
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Belani CP, Singh DA, A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64(4):777-83
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Giantonio BJ, Levy DE, Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):4143
   PubMedGoogle Scholar
• Zhu AX, Stuart K, Blaszkowsky LS, Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110(3):581-9
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Wilkens L, Gebel M, A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):4598
   Google Scholar
• Louafi S, Hebbar M, Rosmorduc O, Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):4594
   Google Scholar
• Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25(27):3787-800
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Youssoufian H, Tonra JR, IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13(18 Pt 2):5549s-55s
   PubMed Web of Science ®Google Scholar
• Higano CS, Yu EY, Whiting SH, A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):3505
   Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
   PubMed Web of Science ®Google Scholar
• Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6(5):322-7
   PubMed Web of Science ®Google Scholar
• Giannelli G, Sgarra C, Porcelli L, EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 2008;262(2):257-64
   PubMed Web of Science ®Google Scholar
• Oseini AM, Roberts LR. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 2009;13(4):443-54
   PubMed Web of Science ®Google Scholar
• Franovic A, Gunaratnam L, Smith K, Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 2007;104(32):13092-7
   PubMed Web of Science ®Google Scholar
• Xiao GH, Jeffers M, Bellacosa A, Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98(1):247-52
   PubMed Web of Science ®Google Scholar
• Wang L, Wang WL, Zhang Y, Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007;37(5):389-96
   PubMed Web of Science ®Google Scholar
• Villanueva A, Chiang DY, Newell P, Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135(6):1972-83, 83 e1-11
   PubMed Web of Science ®Google Scholar
• Rogers R, Ouellet G, Brown C, Cross-talk between the Akt and NF-kappaB signaling pathways inhibits MEHP-induced germ cell apoptosis. Toxicol Sci 2008;106(2):497-508
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Chan TO, Ahmed NN, Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998;17(3):313-25
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Wohlschlaeger J, Lang H, Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48(1):83-90
   PubMed Web of Science ®Google Scholar
• Sahin F, Kannangai R, Adegbola O, mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10(24):8421-5
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5(8):671-88
   PubMed Web of Science ®Google Scholar
• Liu H, Pan Z, Li A, Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008;5(5):373-8
   PubMed Web of Science ®Google Scholar
• Xiang ZL, Zeng ZC, Tang ZY, Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 2009;9:176
   PubMedGoogle Scholar
• Leufgen H, Bihl MP, Rudiger JJ, Collagenase expression and activity is modulated by the interaction of collagen types, hypoxia, and nutrition in human lung cells. J Cell Physiol 2005;204(1):146-54
   PubMed Web of Science ®Google Scholar
• Erler JT, Bennewith KL, Nicolau M, Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440(7088):1222-6
   PubMed Web of Science ®Google Scholar
• Covello KL, Kehler J, Yu H, HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006;20(5):557-70
   PubMed Web of Science ®Google Scholar
• Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17(1):71-7
   PubMed Web of Science ®Google Scholar
• Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004;15(4):229-35
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3(10):721-32
   PubMed Web of Science ®Google Scholar
• Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115(10):2618-24
   PubMed Web of Science ®Google Scholar
• Lee TK, Man K, Ho JW, FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004;25(12):2397-405
   PubMed Web of Science ®Google Scholar
• Crul M, Rosing H, de Klerk GJ, Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38(12):1615-21
   PubMed Web of Science ®Google Scholar
• Van Ummersen L, Binger K, Volkman J, A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004;10(22):7450-6
   PubMed Web of Science ®Google Scholar
• Liu F, Wang P, Jiang X, Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008;99(10):2055-61
   PubMed Web of Science ®Google Scholar
• Semela D, Piguet AC, Kolev M, Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007;46(5):840-8
   PubMed Web of Science ®Google Scholar
• Huynh H, Chow KH, Soo KC, RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009;13(7):1371-80
   PubMed Web of Science ®Google Scholar
• Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72(Suppl 1):30-44
   PubMedGoogle Scholar
• Rizell M, Andersson M, Cahlin C, Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008;13(1):66-70
   PubMed Web of Science ®Google Scholar
• Lev S, Moreno H, Martinez R, Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 1995;376(6543):737-45
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26(22):3279-90
   PubMed Web of Science ®Google Scholar
• McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 1997;26(6):1484-91
   PubMed Web of Science ®Google Scholar
• Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997;236(1):54-8
   PubMed Web of Science ®Google Scholar
• Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001;20(20):2606-10
   PubMed Web of Science ®Google Scholar
• Lee HC, Tian B, Sedivy JM, Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006;131(4):1208-17
   PubMed Web of Science ®Google Scholar
• Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3(6):573-88
   PubMed Web of Science ®Google Scholar
• Carloni V, Vizzutti F, Pantaleo P. Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. Clin Cancer Res 2005;11(11):4266-74
   PubMed Web of Science ®Google Scholar
• Wentz SC, Wu H, Yip-Schneider MT, Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg 2008;12(1):30-7
   PubMed Web of Science ®Google Scholar
• Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007;6(1):138-46
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34
   PubMed Web of Science ®Google Scholar
• Poon RT, Ng IO, Lau C, Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002;20(7):1775-85
   PubMed Web of Science ®Google Scholar
• Yao DF, Wu XH, Zhu Y, Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005;4(2):220-6
   PubMedGoogle Scholar
• Yoshiji H, Kuriyama S, Yoshii J, Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998;28(6):1489-96
   PubMed Web of Science ®Google Scholar
• Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000;124(7):1061-5
   PubMed Web of Science ®Google Scholar
• Zhao J, Hu J, Cai J, Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin Med J (Engl) 2003;116(5):772-6
   PubMed Web of Science ®Google Scholar
• Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 2005;11(11):1705-8
   PubMed Web of Science ®Google Scholar
• Imura S, Miyake H, Izumi K, Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma. J Med Invest 2004;51(3-4):202-9
   PubMedGoogle Scholar
• Moon WS, Rhyu KH, Kang MJ, Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003;16(6):552-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Poon RT, Li Q, Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005;65(9):3691-9
   PubMed Web of Science ®Google Scholar
• Finn RS, Bentley G, Britten CD, Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009;29(2):284-90
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26(18):2992-8
   PubMed Web of Science ®Google Scholar
• Boige V, Baey C, Dromain C, Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. J Clin Oncol (Meeting Abstracts) 2009;27(15S):4597
   Google Scholar
• Thomas MB, Morris JS, Chadha R, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27(6):843-50
   PubMed Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-903
   PubMed Web of Science ®Google Scholar
• Sun W, Haller DG, Mykulowycz K, Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):4574
   Google Scholar
• Hsu C, Yang T, Toh H, Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):15190
   Google Scholar
• Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Targeted therapy of renal cell cancer. Curr Opin Investig Drugs 2008;9(6):570-5
   PubMed Web of Science ®Google Scholar
• Koeberle D, Montemurro M, Samaras P, Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23). J Clin Oncol (Meeting Abstracts) 2009;27(15S):4591
   PubMedGoogle Scholar
• Zhu AX, Sahani DV, Duda DG, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27(18):3027-35
   PubMed Web of Science ®Google Scholar
• Raoul JL, Finn RS, Kang YK, An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts) 2009;27(15S):4577
   Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(26):4293-300
   PubMed Web of Science ®Google Scholar
• Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8(11):1743-9
   PubMed Web of Science ®Google Scholar